Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells

Akhabue K Okojie1,2, Joseph O Uweru3,4, Morgan A Coburn3,4

  • 1Department of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA, USA. gsg4pb@virginia.edu.

PubMed

Insights

Pexidartinib (PLX) effectively depletes microglia in the brain but has minimal impact on most peripheral immune cells. However, PLX treatment reduced certain immune cells in the heart and altered cytokine profiles during LPS stimulation.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Microglia are central nervous system immune cells dependent on CSF1R signaling for maintenance.
  • Pexidartinib (PLX3397) inhibits CSF1R and depletes microglia, but concerns exist regarding peripheral immune cell effects.

Purpose of the Study:

  • To investigate the effects of Pexidartinib (PLX3397) on peripheral immune cell populations in lymphoid and non-lymphoid organs.
  • To assess PLX3397's impact on immune responses during lipopolysaccharide (LPS) challenge.

Main Methods:

  • Mice were treated with PLX3397 chow (660 mg/kg for 7 days) and subsequently stimulated with LPS (1 mg/kg).
  • Flow cytometry was used to analyze immune cell populations in the brain, spleen, bone marrow, kidney, lungs, and heart.
  • Cytokine levels in serum and brain were measured, and locomotor activity was assessed.

Main Results:

  • PLX3397 significantly reduced microglia markers in the brain but had minimal effects on peripheral immune cells, except for a decrease in CD3+ cells and monocytes in the heart.
  • LPS stimulation led to a reduction in innate immune cells, and PLX3397 treatment significantly reduced TNFα, IL-1α, IFN-γ, and IL-1β in LPS-stimulated mice.
  • PLX3397 did not affect locomotor activity, suggesting microglia are not essential for LPS-induced sickness behavior.

Conclusions:

  • Pexidartinib (PLX3397) primarily targets microglia in the CNS with limited off-target effects on most peripheral immune cells.
  • PLX3397 can modulate systemic cytokine responses during inflammation, particularly in LPS-challenged mice.
  • The study provides a comprehensive resource for understanding the systemic immune consequences of PLX3397 treatment.